

Detailed Table of Contents

Chapter 1 Genetics and Pathogenesis of

Psoriasis and Psoriatic Arthritis	17
Genetics of Psoriasis.....	17
Genetics of PsA.....	18
Pathogenesis of Psoriasis.....	19
Pathogenesis of PsA.....	25

Chapter 2 Epidemiology and Classification of

Psoriasis and Psoriatic Arthritis	29
Psoriasis.....	29
Classification of Psoriasis.....	30
Clinical Appearance of Lesions.....	30
Psoriatic Arthritis.....	32
Classification of PsA.....	33
CASPAR Criteria.....	34
Features of PsA.....	34
Laboratory Findings.....	39
Differential Diagnosis of PsA.....	39

Chapter 3 Clinical Presentation of Psoriatic Arthritis

Patterns of Joint Involvement.....	43
Asymmetrical Oligoarthritis.....	44
Symmetrical Polyarthritis.....	44
DIP-Predominant Arthritis.....	45
Axial Arthritis.....	45
Arthritis Mutilans.....	46
Enthesitis.....	48
Dactylitis.....	49
Nail Changes.....	50
Inflammatory Eye Disease.....	51
SAPHO Syndrome.....	51

Chapter 4 Clinical Presentation and

Subtypes of Psoriasis	53
Plaque Psoriasis.....	53
Guttate Psoriasis.....	55
Palmar-Plantar Psoriasis.....	56
Pustular Psoriasis.....	59
Erythrodermic Psoriasis.....	61
Special Locations of Psoriasis.....	62
Inverse Psoriasis.....	62
Genital Psoriasis.....	63
Nail Psoriasis.....	64
Laboratory Evaluation of Psoriasis: Histopathology.....	65

Chapter 5 Diagnosis and Evaluation of

Psoriatic Arthritis	69
----------------------------------	----

History.....	69
Joint Exam.....	70
Enthesal Exam.....	71
Dactylitis.....	73
Axial Evaluation.....	74
Nail Changes.....	79
Laboratory Testing.....	79
Composite Disease Activity Scores.....	82
Radiographic Evaluation.....	84
Other Imaging Modalities.....	86

Chapter 6 Nonbiologic Therapy for

Psoriatic Arthritis	91
Nonsteroidal Anti-inflammatory Drugs.....	91
Corticosteroids.....	92
DMARDs.....	92
Cyclosporine.....	94
Lefunomide.....	94
Methotrexate.....	94
Apremilast.....	96
Tofacitinib.....	103
Upadacitinib.....	111
Treatment Guidance.....	116
Group for Research and Assessment of Psoriasis and PsA (GRAPPA).....	121
2018 ACR/NPF Guidelines for the Treatment of PsA.....	124

Chapter 7 TNF Inhibitor Therapy for

Psoriatic Arthritis	137
Etanercept.....	140
Infliximab.....	145
Adalimumab.....	150
Golimumab.....	155
Certolizumab Pegol.....	158
Safety.....	160
Infections.....	161
Tuberculosis.....	161
Hepatitis B.....	162
Herpes Zoster.....	162
Lymphoma.....	162
Demyelinating Disease and CHF.....	163
Injection Site Reactions.....	163
Lab Abnormalities.....	163
Pregnancy.....	163
General Management.....	164

Chapter 8 Other Biologic Therapy for Psoriatic Arthritis	169	Acitretin Efficacy	237
Psoriatic Arthritis	169	Acitretin Safety	240
Ustekinumab	169	Cyclosporine	240
Risankizumab	175	Cyclosporine Efficacy	241
Interleukin-17 Inhibitors	179	Cyclosporine Safety	241
Secukinumab	179	Apremilast	243
Ixekizumab	185	Apremilast Efficacy	244
Brodalumab	190	Apremilast Safety	246
Conclusions	190	2020 Joint AAD and NPF Guidelines for the Treatment of Psoriasis with Systemic Nonbiologic Therapies ..	247
Abatacept	192	Conclusion	248
Anakinra	195	Chapter 12 Biologic Therapy for Psoriasis	251
Alefacept	196	Anti-TNF Agents	252
Other Biologic Agents	196	Anti-TNF Efficacy	253
Chapter 9 Topical Therapy for Psoriasis	199	Pediatric Psoriasis	267
Emollients and Keratolytics	200	Anti-TNF Safety in Psoriasis	267
Emollients	200	Ustekinumab	269
Keratolytic Agents	201	Efficacy	269
Physiologic Agents	202	Safety	271
Topical Corticosteroids	202	Anti-Interleukin 17 Medications	272
Tapinarof	204	Secukinumab	272
Other Topical Agents	208	Ixekizumab	275
Tar and Anthralin	208	Brodalumab	277
Vitamin D Derivatives	209	Anti-Interleukin 23, P19 Medications	280
Combination Agents	209	Guselkumab	280
Special Case: Inverse and Facial Psoriasis	210	Tildrakizumab	283
Topical Macrolides: Tacrolimus and Pimecrolimus ..	210	Risankizumab	284
2020 Joint AAD and NPF Guidelines for the Treatment of Psoriasis with Topical Therapy	211	Biologic Medications in Development for Psoriasis ...	287
Conclusion	213	2019 Joint AAD and NPF Guidelines for the Treatment of Psoriasis with Biologics	288
Chapter 10 Phototherapy for Psoriasis	217	Conclusion	291
Ultraviolet B Therapy	217	Chapter 13 Coordinated Management of Psoriatic Arthritis and Psoriasis	295
Targeted Phototherapy With UVB	222	The Role of Primary Care	295
Psoralen Plus Ultraviolet A (PUVA) Therapy	223	Identifying PsA in the Dermatology Office	297
Climatotherapy	225	Identifying Psoriasis in the Rheumatology Office	300
2019 Joint AAD and NPF Guidelines for the Treatment of Psoriasis with Phototherapy	225	Co-management of the Patient With PsA and Psoriasis	300
Conclusion	226	Developing a Treatment Plan	302
Chapter 11 Oral Systemic Therapy for Psoriasis	229	Chapter 14 Abbreviations/Acronyms	305
Methotrexate	232		
Methotrexate Efficacy	232		
Methotrexate Safety	234		
Hepatic Toxicity	235		
Hematologic Toxicity	235		
Other Toxicities	236		
Acitretin	237		